{
    "topic": "healthcare",
    "source": "USA TODAY",
    "bias": 1,
    "url": "https://www.usatoday.com/story/news/politics/2018/05/04/advocates-say-trump-has-ground-make-up-drug-prices/576922002/",
    "title": "Trump to deliver major address on drug prices, but advocates predict small steps",
    "date": "2018-05-04",
    "authors": "John Fritze",
    "content": "WASHINGTON \u2014 President Trump is preparing to deliver a long-awaited address on prescription drug prices as soon as next week , but advocates warn the White House may be focused more on populist messaging than swallowing bitter pills .\nTrump lamented the rising cost of drugs during his campaign and last year he accused pharmaceutical companies of \u201c getting away with murder. \u201d He blasted other countries for controlling prices and vowed to the cost of drugs in the U.S. \u201c way down . \u201d\nBut based on more recent statements from the president as well as remarks made by members of his administration \u2014 many of whom previously worked for drug companies \u2014 few expect Trump to offer up major changes in the address .\n\u201c We are not hopeful , but we \u2019 d love to be wrong , \u201d said Peter Maybarduk , director of Public Citizen 's Global Access to Medicines Program . \u201c The signals are pointing mostly in the wrong direction . \u201d\n. @ Merck Pharma is a leader in higher & higher drug prices while at the same time taking jobs out of the U.S. Bring jobs back & LOWER PRICES ! \u2014 Donald J. Trump ( @ realDonaldTrump ) August 14 , 2017\nStudies show the increase in drug prices are having a big impact on American households . An AARP report last year found the average annual price of drugs widely prescribed to seniors increased to $ 12,951 from $ 6,425 five years ago .\nHealth and Human Services Secretary Alex Azar , a former executive at drug maker Eli Lilly , said this week that Trump wants to go \u201c much further \u201d on the issue , but offered few specifics . An unpublished proposal on drug pricing recently submitted to the White House by HHS was marked as having little economic impact , an indication the administration is not contemplating fundamental changes .\nThe White House had previously said Trump would use the speech to ask HHS for ideas to address the problem . The speech was scheduled for April 26 but was delayed when Azar was hospitalized with diverticulitis . A White House spokesman did not respond to questions about the contents of the upcoming address , or its timing .\n\u201c I \u2019 m not expecting significant changes , \u201d said Rachel Sachs , a Washington University law professor who blogs about drug policies . \u201c One of the things to watch for in the speech is what the administration says it can do on its own and what it needs Congress \u2019 help with . \u201d\nTrump has already put pressure on the drug industry in ways that even some critics have applauded . The Food and Drug Administration has sped up approval of generic drugs , injecting more competition in the market . The president \u2019 s proposed budget floated the idea of giving some states leverage to negotiate prices in Medicaid .\nAnd the White House has proposed requiring pharmacy benefit managers , which act as middlemen between drug companies and insurers , to pass along to Medicare beneficiaries the savings they negotiate by buying large quantities of drugs . That idea wouldn \u2019 t lower the price of medicine , but it could reduce out-of-pocket costs for patients .\nThe administration has also been scrutinizing lower prices paid in other countries , a favorite issue for the president . White House economic advisers recommended this year that the administration use `` enhanced trade policy '' to pressure other nations against negotiating prices that are far lower than what U.S. patients and insurers will pay .\nAnalysts say many of those proposals could have an impact , but they will take time to implement \u2014 and may affect a small number of patients .\nWhat the president is unlikely to do is allow Medicare to negotiate drug prices . Trump embraced that idea during the presidential campaign but has not pursued it since taking office . Azar said this year that allowing negotiations would limit the choice of drugs available to seniors .\nLess clear is whether the administration will step up enforcement of anti-competitive practices . In the case of price gouging , for instance , federal law allows the government to override patent protection in exchange for compensation . The Bush administration came under pressure to consider that move with the anti-anthrax treatment Cipro in 2001 , but drug maker Bayer decided to voluntarily reduce its price instead .\nFDA Commissioner Scott Gottlieb has hinted that Trump 's address will focus at least in part on those practices . Gottlieb told a conference in Washington on Thursday that the administration wants to `` dismantle many of the provisions that shield parts of the drug industry from more vigorous competition . ''\nMore : Drug prices must come down if copay help is n't the answer , experts agree\nMore : Drug co-pay groups : Critical patient charities or fronts for drugmakers ?\nTrump \u2019 s rhetoric on drug prices has reflected public apprehension on the issue . Just more than half of Americans believe passing legislation to address drug prices should be a \u201c top priority \u201d for Washington , according to a Kaiser Health Tracking Poll in March .\nAnd the added pressure from the White House has also intensified finger pointing within the labyrinth of industries involved in prescriptions . Pharmaceutical companies blame insurers and pharmacy benefit managers . Those groups counter that it is the drug makers that decide how much to charge for their product .\n\u201c The problem is the price , \u201d said Will Holley , a spokesman for the Campaign for Sustainable Rx Pricing , which represents insurers and large PBMs such as CVS Health . \u201c At the end of the day there \u2019 s one player that sets the price of drugs . \u201d\nHolly Campbell , a spokeswoman for the trade group Pharmaceutical Research and Manufacturers of America , said patients are struggling to afford medicine `` because insurers and PBMs have been shifting more of the costs to them for years . ''\nDrug prices , she said , grew relatively slowly in 2017 `` while patients ' out-of-pocket costs continue to skyrocket . ''",
    "content_original": "CLOSE\n\nPresident Donald Trump speaks during the the National Teacher of the Year reception in the East Room of the White House in Washington, Wednesday, May 2, 2018. (AP Photo/Carolyn Kaster) ORG XMIT: OTKCK102 (Photo: Carolyn Kaster, AP)\n\nWASHINGTON \u2014 President Trump is preparing to deliver a long-awaited address on prescription drug prices as soon as next week, but advocates warn the White House may be focused more on populist messaging than swallowing bitter pills.\n\nTrump lamented the rising cost of drugs during his campaign and last year he accused pharmaceutical companies of \u201cgetting away with murder.\u201d He blasted other countries for controlling prices and vowed to the cost of drugs in the U.S. \u201cway down.\u201d\n\nBut based on more recent statements from the president as well as remarks made by members of his administration \u2014 many of whom previously worked for drug companies \u2014 few expect Trump to offer up major changes in the address.\n\n\u201cWe are not hopeful, but we\u2019d love to be wrong,\u201d said Peter Maybarduk, director of Public Citizen's Global Access to Medicines Program. \u201cThe signals are pointing mostly in the wrong direction.\u201d\n\n.@Merck Pharma is a leader in higher & higher drug prices while at the same time taking jobs out of the U.S. Bring jobs back & LOWER PRICES! \u2014 Donald J. Trump (@realDonaldTrump) August 14, 2017\n\nStudies show the increase in drug prices are having a big impact on American households. An AARP report last year found the average annual price of drugs widely prescribed to seniors increased to $12,951 from $6,425 five years ago.\n\nHealth and Human Services Secretary Alex Azar, a former executive at drug maker Eli Lilly, said this week that Trump wants to go \u201cmuch further\u201d on the issue, but offered few specifics. An unpublished proposal on drug pricing recently submitted to the White House by HHS was marked as having little economic impact, an indication the administration is not contemplating fundamental changes.\n\nThe White House had previously said Trump would use the speech to ask HHS for ideas to address the problem. The speech was scheduled for April 26 but was delayed when Azar was hospitalized with diverticulitis. A White House spokesman did not respond to questions about the contents of the upcoming address, or its timing.\n\n\u201cI\u2019m not expecting significant changes,\u201d said Rachel Sachs, a Washington University law professor who blogs about drug policies. \u201cOne of the things to watch for in the speech is what the administration says it can do on its own and what it needs Congress\u2019 help with.\u201d\n\nTrump has already put pressure on the drug industry in ways that even some critics have applauded. The Food and Drug Administration has sped up approval of generic drugs, injecting more competition in the market. The president\u2019s proposed budget floated the idea of giving some states leverage to negotiate prices in Medicaid.\n\nAnd the White House has proposed requiring pharmacy benefit managers, which act as middlemen between drug companies and insurers, to pass along to Medicare beneficiaries the savings they negotiate by buying large quantities of drugs. That idea wouldn\u2019t lower the price of medicine, but it could reduce out-of-pocket costs for patients.\n\nThe administration has also been scrutinizing lower prices paid in other countries, a favorite issue for the president. White House economic advisers recommended this year that the administration use \"enhanced trade policy\" to pressure other nations against negotiating prices that are far lower than what U.S. patients and insurers will pay.\n\nAnalysts say many of those proposals could have an impact, but they will take time to implement \u2014 and may affect a small number of patients.\n\n\u201cThese are all tweaks around the edges,\u201d Sachs said.\n\nWhat the president is unlikely to do is allow Medicare to negotiate drug prices. Trump embraced that idea during the presidential campaign but has not pursued it since taking office. Azar said this year that allowing negotiations would limit the choice of drugs available to seniors.\n\nLess clear is whether the administration will step up enforcement of anti-competitive practices. In the case of price gouging, for instance, federal law allows the government to override patent protection in exchange for compensation. The Bush administration came under pressure to consider that move with the anti-anthrax treatment Cipro in 2001, but drug maker Bayer decided to voluntarily reduce its price instead.\n\nFDA Commissioner Scott Gottlieb has hinted that Trump's address will focus at least in part on those practices. Gottlieb told a conference in Washington on Thursday that the administration wants to \"dismantle many of the provisions that shield parts of the drug industry from more vigorous competition.\"\n\nMore: Drug prices must come down if copay help isn't the answer, experts agree\n\nMore: Drug co-pay groups: Critical patient charities or fronts for drugmakers?\n\nTrump\u2019s rhetoric on drug prices has reflected public apprehension on the issue. Just more than half of Americans believe passing legislation to address drug prices should be a \u201ctop priority\u201d for Washington, according to a Kaiser Health Tracking Poll in March.\n\nAnd the added pressure from the White House has also intensified finger pointing within the labyrinth of industries involved in prescriptions. Pharmaceutical companies blame insurers and pharmacy benefit managers. Those groups counter that it is the drug makers that decide how much to charge for their product.\n\n\u201cThe problem is the price,\u201d said Will Holley, a spokesman for the Campaign for Sustainable Rx Pricing, which represents insurers and large PBMs such as CVS Health. \u201cAt the end of the day there\u2019s one player that sets the price of drugs.\u201d\n\nHolly Campbell, a spokeswoman for the trade group Pharmaceutical Research and Manufacturers of America, said patients are struggling to afford medicine \"because insurers and PBMs have been shifting more of the costs to them for years.\"\n\nDrug prices, she said, grew relatively slowly in 2017 \"while patients' out-of-pocket costs continue to skyrocket.\"\n\nRead or Share this story: https://usat.ly/2Id0vVM",
    "source_url": "www.usatoday.com",
    "bias_text": "center",
    "ID": "qcEY34fKAqRKYeBt"
}